New injection shows promise against fatty liver scarring
NCT ID NCT07024212
First seen Feb 01, 2026 · Last updated May 01, 2026 · Updated 15 times
Summary
This study tests an investigational drug called DR10624 in 110 adults with fatty liver disease (MASLD) who are at high risk for liver scarring (fibrosis). The goal is to see if the drug can safely reduce liver fat and stiffness compared to a placebo. Participants receive injections and are monitored for 12 weeks using MRI and other scans.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MASLD are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Nanjing Gulou Hospital
Nanjing, China
-
Prince of Wales Hospital, The Chinese University of Hong Kong
Hong Kong, Hong Kong, Hong Kong
-
The Affiliated Hospital of Hangzhou Normal University
Hangzhou, Zhejiang, China
-
The First Hospital of Jilin University
Changchun, China
Conditions
Explore the condition pages connected to this study.